TISSUE-BASED SMALL ANIMAL MODEL FOR HIV DRUG DISCOVERY

美国国家过敏症和传染病研究所(NIAID)支持一系列全面的合同资源，以发现和开发新的治疗药物，用于预防和治疗由人类免疫缺陷病毒-1(HIV-1)、艾滋病相关机会性病原体和其他感染剂引起的感染。动物模型资源构成了该药物发现和开发计划的一个要素。本项目的目的是为评估艾滋病毒-1感染的潜在疗法提供资源。有关科学界访问的详细信息，请访问： Http://www.niaid.nih.gov/daids/pdatguide/overview.htm 承包商负责：1)单独和联合评价治疗药物在体外和SCID-HU胸腺/肝脏动物模型中的疗效和毒性；ii)对体外和体内检测系统的组件进行质量保证/控制，以确保对候选疗法的可重复性评价；iii)确定最佳给药路线和时间表；iv)根据需要修改模型系统，以增加其对于评估潜在HIV-1疗法的有效性；以及5)编写和提交定期和中期报告。

The National Institute of Allergy and Infectious Diseases (NIAID) supports a comprehensive portfolio of contract resources to discover and develop novel therapeutic agents for the prevention and treatment of infections caused by Human Immunodeficiency Virus-1 (HIV-1), AIDS-associated opportunistic pathogens, and other infectious agents. Animal model resources constitute one element of this drug discovery and development program. The purpose of the present project is to provide a resource for evaluating potential therapeutics for HIV-1 infection. Details regarding access by the scientific community are provided at: http://www.niaid.nih.gov/daids/pdatguide/overview.htm The contractor is responsible for i) evaluating therapeutic agents, alone and in combination, for efficacy and toxicity in vitro and in the SCID-hu thymus/liver animal model; ii) performing quality assurance/control of the components of the in vitro and in vivo assay systems, to insure reproducible evaluation of candidate therapies; iii) determining optimal routes and schedules of administration; iv) modifying the model system as necessary, to augment its usefulness for evaluating potential HIV-1 therapeutics; and 5) preparing and submitting periodic and interim reports.